NASDAQ:ARMO - ARMO BioSciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$49.85 -0.05 (-0.10 %)
(As of 05/22/2018 11:43 AM ET)
Previous Close$49.90
Today's Range$49.85 - $49.90
52-Week Range$25.10 - $57.19
Volume27,595 shs
Average Volume681,167 shs
Market Capitalization$1.52 billion
P/E Ratio-1.75
Dividend YieldN/A
BetaN/A

About ARMO BioSciences (NASDAQ:ARMO)

ARMO BioSciences logoARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Receive ARMO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARMO
CUSIPN/A
Phone650-779-5075

Debt

Debt-to-Equity RatioN/A
Current Ratio10.82
Quick Ratio10.82

Price-To-Earnings

Trailing P/E Ratio-1.75
Forward P/E Ratio-21.30
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($4.53) per share
Price / Book-11.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees31
Outstanding Shares30,410,000

ARMO BioSciences (NASDAQ:ARMO) Frequently Asked Questions

What is ARMO BioSciences' stock symbol?

ARMO BioSciences trades on the NASDAQ under the ticker symbol "ARMO."

How were ARMO BioSciences' earnings last quarter?

ARMO BioSciences (NASDAQ:ARMO) posted its quarterly earnings data on Monday, April, 2nd. The company reported ($9.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $9.17. View ARMO BioSciences' Earnings History.

What price target have analysts set for ARMO?

4 brokers have issued 1-year price targets for ARMO BioSciences' stock. Their forecasts range from $50.00 to $75.00. On average, they anticipate ARMO BioSciences' share price to reach $63.25 in the next twelve months. View Analyst Ratings for ARMO BioSciences.

Who are some of ARMO BioSciences' key competitors?

Who are ARMO BioSciences' key executives?

ARMO BioSciences' management team includes the folowing people:
  • Dr. Peter Van Vlasselaer, Founder, Pres, CEO & Director (Age 59)
  • Mr. Herbert C. Cross, Chief Financial Officer (Age 46)
  • Dr. Joseph Leveque, Chief Medical Officer (Age 57)
  • Dr. Martin Oft, Founder and VP of Pre-Clinical & Clinical Devel. (Age 51)
  • Dr. Russell T. Kawahata, VP of Technical Operations (Age 64)

When did ARMO BioSciences IPO?

(ARMO) raised $100 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Baird was co-manager.

Has ARMO BioSciences been receiving favorable news coverage?

News coverage about ARMO stock has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ARMO BioSciences earned a news sentiment score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 45.49 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are ARMO BioSciences' major shareholders?

ARMO BioSciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (3.97%), BlackRock Inc. (2.70%), JPMorgan Chase & Co. (1.09%), Redmile Group LLC (0.98%), Wells Fargo & Company MN (0.89%) and Franklin Resources Inc. (0.58%). View Institutional Ownership Trends for ARMO BioSciences.

Which institutional investors are buying ARMO BioSciences stock?

ARMO stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, BlackRock Inc., JPMorgan Chase & Co., Redmile Group LLC, Wells Fargo & Company MN, Franklin Resources Inc., Millennium Management LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for ARMO BioSciences.

How do I buy shares of ARMO BioSciences?

Shares of ARMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ARMO BioSciences' stock price today?

One share of ARMO stock can currently be purchased for approximately $49.86.

How big of a company is ARMO BioSciences?

ARMO BioSciences has a market capitalization of $1.52 billion. The company earns $-42,420,000.00 in net income (profit) each year or ($28.52) on an earnings per share basis. ARMO BioSciences employs 31 workers across the globe.

How can I contact ARMO BioSciences?

ARMO BioSciences' mailing address is 575 Chesapeake Drive, Redwood City CA, 94063. The company can be reached via phone at 650-779-5075 or via email at [email protected]


MarketBeat Community Rating for ARMO BioSciences (ARMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  56
MarketBeat's community ratings are surveys of what our community members think about ARMO BioSciences and other stocks. Vote "Outperform" if you believe ARMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARMO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ARMO BioSciences (NASDAQ:ARMO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for ARMO BioSciences in the last 12 months. Their average twelve-month price target is $63.25, suggesting that the stock has a possible upside of 26.88%. The high price target for ARMO is $75.00 and the low price target for ARMO is $50.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyN/A
Consensus Rating Score: 2.253.002.75N/A
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $63.25$63.25$67.6667N/A
Price Target Upside: 26.88% upside58.24% upside33.25% upsideN/A

ARMO BioSciences (NASDAQ:ARMO) Consensus Price Target History

Price Target History for ARMO BioSciences (NASDAQ:ARMO)

ARMO BioSciences (NASDAQ:ARMO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018Robert W. BairdDowngradeOutperform ➝ Neutral$67.00N/AView Rating Details
5/10/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$75.00N/AView Rating Details
5/10/2018Leerink SwannDowngradeOutperform ➝ Market Perform$50.00N/AView Rating Details
2/20/2018Jefferies GroupInitiated CoverageBuy ➝ Buy$61.00LowView Rating Details
(Data available from 5/22/2016 forward)

Earnings

ARMO BioSciences (NASDAQ:ARMO) Earnings History and Estimates Chart

Earnings by Quarter for ARMO BioSciences (NASDAQ:ARMO)

ARMO BioSciences (NASDAQ:ARMO) Earnings Estimates

2018 EPS Consensus Estimate: ($2.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.59)($0.38)($0.49)
Q2 20182($0.66)($0.42)($0.54)
Q3 20182($0.76)($0.47)($0.62)
Q4 20182($0.82)($0.50)($0.66)

ARMO BioSciences (NASDAQ ARMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018Q4 2017($0.45)($9.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ARMO BioSciences (NASDAQ:ARMO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ARMO BioSciences (NASDAQ ARMO) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 40.93%
Insider Trading History for ARMO BioSciences (NASDAQ:ARMO)
Institutional Ownership by Quarter for ARMO BioSciences (NASDAQ:ARMO)

ARMO BioSciences (NASDAQ ARMO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

ARMO BioSciences (NASDAQ ARMO) News Headlines

Source:
DateHeadline
 Brokerages Anticipate ARMO BioSciences (ARMO) Will Post Earnings of -$0.48 Per Share Brokerages Anticipate ARMO BioSciences (ARMO) Will Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - May 18 at 11:23 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of ARMO BioSciences, Inc. - ARMOSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of ARMO BioSciences, Inc. - ARMO
finance.yahoo.com - May 18 at 3:24 PM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMOSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMO
finance.yahoo.com - May 17 at 8:09 AM
Eli Lilly Had Good Reason To Spend $1.6B On ArmoEli Lilly Had Good Reason To Spend $1.6B On Armo
seekingalpha.com - May 16 at 3:22 PM
Star Kleiner Perkins VC may be launching her own firmStar Kleiner Perkins VC may be launching her own firm
finance.yahoo.com - May 15 at 3:24 PM
WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholdersWeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders
finance.yahoo.com - May 14 at 3:21 PM
ARMO BioSciences (ARMO) & Its Rivals Critical ReviewARMO BioSciences (ARMO) & Its Rivals Critical Review
www.americanbankingnews.com - May 13 at 5:28 AM
Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA DateYour Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date
seekingalpha.com - May 11 at 3:21 PM
BRIEF-Armo Biosciences - Upon Termination Of Merger Under Specified Circumstances Co May Be Required To Pay Eli Lilly Fee Of $63.4 MlnBRIEF-Armo Biosciences - Upon Termination Of Merger Under Specified Circumstances Co May Be Required To Pay Eli Lilly Fee Of $63.4 Mln
www.reuters.com - May 11 at 7:51 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMOSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMO
finance.yahoo.com - May 11 at 7:51 AM
What Should Investors Know About The Future Of ARMO BioSciences Inc’s (NASDAQ:ARMO)?What Should Investors Know About The Future Of ARMO BioSciences Inc’s (NASDAQ:ARMO)?
finance.yahoo.com - May 11 at 7:51 AM
Stealth Rally: Cramers Mad Money Recap (Thursday 5/10/18)Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)
finance.yahoo.com - May 11 at 7:51 AM
ARMO BioSciences (ARMO) Downgraded by Leerink Swann to "Market Perform"ARMO BioSciences (ARMO) Downgraded by Leerink Swann to "Market Perform"
www.americanbankingnews.com - May 10 at 7:51 PM
UPDATE 3-Lilly to buy Armo Biosciences for $1.6 bln to bolster cancer pipelineUPDATE 3-Lilly to buy Armo Biosciences for $1.6 bln to bolster cancer pipeline
www.reuters.com - May 10 at 3:22 PM
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc.ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc.
finance.yahoo.com - May 10 at 3:22 PM
ARMO Biosciences Soars 67% on $1.6 Billion BuyoutARMO Biosciences Soars 67% on $1.6 Billion Buyout
www.msn.com - May 10 at 3:22 PM
ARMO BioSciences (ARMO) Downgraded by Robert W. Baird to NeutralARMO BioSciences (ARMO) Downgraded by Robert W. Baird to Neutral
www.americanbankingnews.com - May 10 at 3:06 PM
ARMO BioSciences (ARMO) Downgraded by BMO Capital MarketsARMO BioSciences (ARMO) Downgraded by BMO Capital Markets
www.americanbankingnews.com - May 10 at 1:28 PM
Lilly to acquire ARMO BioSciences for $1.6BLilly to acquire ARMO BioSciences for $1.6B
seekingalpha.com - May 10 at 7:52 AM
Eli Lilly To Acquire ARMO BioSciences For Approx. $1.6 Bln - Quick FactsEli Lilly To Acquire ARMO BioSciences For Approx. $1.6 Bln - Quick Facts
www.nasdaq.com - May 10 at 7:52 AM
Eli Lilly will buy ARMO Biosciences for $1.6 blnEli Lilly will buy ARMO Biosciences for $1.6 bln
www.marketwatch.com - May 10 at 7:52 AM
Lilly Announces Agreement To Acquire ARMO BioSciencesLilly Announces Agreement To Acquire ARMO BioSciences
finance.yahoo.com - May 10 at 7:52 AM
Lilly to buy Armo Biosciences for $1.6 billionLilly to buy Armo Biosciences for $1.6 billion
finance.yahoo.com - May 10 at 7:52 AM
My Favorite Investment For The Coming Biotech Bull Market (Bhavneesh Sharma)My Favorite Investment For The Coming Biotech Bull Market (Bhavneesh Sharma)
seekingalpha.com - May 7 at 3:22 PM
ValuEngine Upgrades ARMO BioSciences (ARMO) to "Hold"ValuEngine Upgrades ARMO BioSciences (ARMO) to "Hold"
www.americanbankingnews.com - May 4 at 12:54 AM
ARMO BioSciences (ARMO) Receives Average Recommendation of "Buy" from BrokeragesARMO BioSciences (ARMO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 3:34 AM
 Analysts Anticipate ARMO BioSciences (ARMO) to Announce -$0.48 Earnings Per Share Analysts Anticipate ARMO BioSciences (ARMO) to Announce -$0.48 Earnings Per Share
www.americanbankingnews.com - May 1 at 11:18 AM
Zacks: Analysts Set $63.25 Price Target for ARMO BioSciences (ARMO)Zacks: Analysts Set $63.25 Price Target for ARMO BioSciences (ARMO)
www.americanbankingnews.com - April 28 at 7:52 AM
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 26 at 7:40 AM
ARMO BioSciences (ARMO) Downgraded by Zacks Investment Research to "Sell"ARMO BioSciences (ARMO) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 24 at 5:22 PM
Financial Survey: ARMO BioSciences (ARMO) & The CompetitionFinancial Survey: ARMO BioSciences (ARMO) & The Competition
www.americanbankingnews.com - April 19 at 7:21 PM
New Research: Key Drivers of Growth for Maiden, Oaktree Capital Group, Broa ...New Research: Key Drivers of Growth for Maiden, Oaktree Capital Group, Broa ...
globenewswire.com - April 18 at 3:21 PM
-$0.48 EPS Expected for ARMO BioSciences (ARMO) This Quarter-$0.48 EPS Expected for ARMO BioSciences (ARMO) This Quarter
www.americanbankingnews.com - April 14 at 1:25 PM
Short Interest in ARMO BioSciences (ARMO) Expands By 86.2%Short Interest in ARMO BioSciences (ARMO) Expands By 86.2%
www.americanbankingnews.com - April 14 at 1:40 AM
 ARMO BioSciences (ARMO) Given $63.25 Average Price Target by Brokerages ARMO BioSciences (ARMO) Given $63.25 Average Price Target by Brokerages
www.americanbankingnews.com - April 13 at 3:29 AM
FY2020 EPS Estimates for ARMO BioSciences Raised by Leerink Swann (ARMO)FY2020 EPS Estimates for ARMO BioSciences Raised by Leerink Swann (ARMO)
www.americanbankingnews.com - April 5 at 8:46 AM
ARMO BioSciences Expected to Post Q1 2018 Earnings of ($0.38) Per Share (ARMO)ARMO BioSciences Expected to Post Q1 2018 Earnings of ($0.38) Per Share (ARMO)
www.americanbankingnews.com - April 4 at 6:28 AM
ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy ConferenceARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference
finance.yahoo.com - April 3 at 3:19 PM
ARMO BioSciences (ARMO) Issues Quarterly  Earnings ResultsARMO BioSciences (ARMO) Issues Quarterly Earnings Results
www.americanbankingnews.com - April 3 at 9:21 AM
ARMO BioSciences Reports FY 2017 Financial ResultsARMO BioSciences Reports FY 2017 Financial Results
finance.yahoo.com - April 2 at 3:19 PM
Zacks: ARMO BioSciences (ARMO) Given $63.25 Average Target Price by AnalystsZacks: ARMO BioSciences (ARMO) Given $63.25 Average Target Price by Analysts
www.americanbankingnews.com - March 29 at 9:32 PM
BRIEF-Armo Biosciences Enrolls Patient In The Cypress 2 Trial Evaluating AM0010BRIEF-Armo Biosciences Enrolls Patient In The Cypress 2 Trial Evaluating AM0010
www.reuters.com - March 29 at 3:19 PM
ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung CancerARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer
finance.yahoo.com - March 29 at 3:19 PM
ARMO BioSciences Expected to Post FY2017 Earnings of ($2.40) Per Share (ARMO)ARMO BioSciences Expected to Post FY2017 Earnings of ($2.40) Per Share (ARMO)
www.americanbankingnews.com - March 29 at 7:57 AM
ARMO BioSciences (ARMO) Expected to Post Earnings of -$0.12 Per ShareARMO BioSciences (ARMO) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - March 28 at 1:24 PM
Leerink: Armo Biosciences Promising Data Justifies A Bullish StanceLeerink: Armo Biosciences' 'Promising' Data Justifies A Bullish Stance
www.msn.com - March 27 at 3:18 PM
ARMO BioSciences (ARMO) Upgraded to "Outperform" at Leerink SwannARMO BioSciences (ARMO) Upgraded to "Outperform" at Leerink Swann
www.americanbankingnews.com - March 27 at 8:45 AM
 Analysts Set $63.25 Price Target for ARMO BioSciences (ARMO) Analysts Set $63.25 Price Target for ARMO BioSciences (ARMO)
www.americanbankingnews.com - March 26 at 11:28 PM
ARMO BioSciences (ARMO) Reports Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer StudyARMO BioSciences (ARMO) Reports Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
www.streetinsider.com - March 26 at 3:18 PM
ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer StudyARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
finance.yahoo.com - March 26 at 3:18 PM

SEC Filings

ARMO BioSciences (NASDAQ:ARMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ARMO BioSciences (NASDAQ ARMO) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.